Related Experiment Videos
Fosfomycin trometamol: historical background and clinical development
1Chair of Chemotherapy, Padiglione Forlanini, Pavia, Italy.
Infection
|January 1, 1990
Summary
Fosfomycin trometamol offers a single-dose therapy for urinary tract infections, achieving high urinary concentrations to prevent resistance. This broad-spectrum antibiotic demonstrates excellent therapeutic activity and tolerability.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Fosfomycin possesses broad-spectrum antimicrobial activity and good tolerability.
- Challenges with fosfomycin include rapid emergence of resistant strains and poor oral bioavailability.
- Fosfomycin trometamol, a salt with tromethamine, was developed to address these limitations.
Observation:
- Oral administration of fosfomycin trometamol results in high and sustained urinary concentrations for up to 48 hours.
- This pharmacokinetic profile ensures prolonged bactericidal activity within the urinary tract.
- The sustained activity helps in preventing the emergence of resistant bacterial variants.
Findings:
- Fosfomycin trometamol is effective for single-dose therapy of lower uncomplicated urinary tract infections.
- Clinical trials confirm its excellent therapeutic efficacy in this specific indication.
- The drug's properties support its use in preventing antimicrobial resistance.
Implications:
- Fosfomycin trometamol represents a valuable therapeutic option for managing urinary tract infections.
- Its pharmacokinetic advantages may contribute to antimicrobial stewardship efforts.
- The single-dose regimen enhances patient compliance and convenience.